Icon

LAMICTAL CD (nda020764)- (2MG,5MG,25MG,100MG)

LAMOTRIGINE GLAXOSMITHKLINE LLC
2MG,5MG,25MG,100MG
Yes No
2012-Jul-29 Expired
None None
None No
LAMICTAL is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: • partial-onset seizures. • primary generalized tonic-clonic seizures. • generalized seizures of Lennox-Gastaut syndrome. Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. Bipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy.
7 0 6
Total Other Developers None
Drugs with Suitability Yes
2MG ** ** - - -
5MG ** ** - - 3
25MG ** ** Up - 4
100MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 6
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ** ****** **** *** **. *****'* ************ ******* *********** ****** **. **, ** ****, ** **** & ** ****, ********** ******* *** ******, *******-********** ********,, *******-**********, ********* ******, ***** (***) ***
****** ***** ****** *** *** ***** ************ ******* *********** ****** **. ***, *** *** ***, ******* ***** *. *. **. ** *******-*******, ******-****** *********, *********, ******* ******, ***** (***) ***
****** ***** ****** *** *** ***** ************ ******* *********** ******* ****** *****, *.*. *****, ******-********, *****, ******** ******* ******, ***** (***) ***
****** ******** ****** *** ******** *************** ******* *********** **** ** *-*, ******* ********** ******, *******-******,, ***, ** ******, ***** (***) ***
****** **** **** ************** ********** ***. *********** ** ******* ******, ***** ***, *******, ****** (***) ***
****** ********* ****** ********* ****** ******* *********** ****-***, **. **.*** & ***, **********, ********** ******, *******-********** ********, *******, ********* ******, ***** (***) ***
****** ******* ******* *************** ******* *********** *********** ********, ******* *******, *.*. *******, **** *****, ****** *****,, **********, ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.